Purpose: In this study, the role of hyper-radiation sensitivity (HRS) in potentiating the effects of cisplatin by low dose fractionated radiation (LDFRT) was evaluated in four human non-small cell lung cancer cell lines. Experimental Design: Presence of HRS and cisplatin enhancement ratio (CER) by LDFRT/2Gy was assessed using colony-forming and apoptotic assays. Cell cycle disturbances were studied by flow-cytometry. Expression of genes involved in apoptosis was assessed using real-time RT-PCR arrays. Results: H-157 cells showed a distinct HRS region followed by UKY-29 and A549 cells while it was absent in H460 cells. H460 cells that lack HRS showed maximum CER with LDFRT (4x0.5Gy) both by clonogenic inhibition and apoptosis compared to single fraction of 2Gy while the most radio-resistant A549 cells had the least CER with no significant differences between LDFRT or 2Gy. Interestingly, in H157 cells a more pronounced CER was observed with LDFRT when assessed by apoptosis but by clonogenic inhibition CER was higher with 2Gy than LDFRT. Excluding H-157 cells, the CER by LDFRT was inversely proportional to radioresistance (determined by D 0 or SF 2 ) of the cells. LDFRT alone or in combination with cisplatin induced larger number of pro-apoptotic genes than 2Gy or cisplatin+2Gy in cells showing HRS when compared to H460 cells. Conclusion:
INTRODUCTION
Combined treatment with radiotherapy and chemotherapy has been extensively used in the management of many types of solid malignancies including non-small cell lung cancer (NSCLC) (1, 2) . This approach in NSCLC has demonstrated increased response rate, survival and local control rate (1, 3, 4) . Cis-diamminedichloroplatinum (5) (cisplatin) is one of the most widely used chemotherapeutic agents. While several studies have shown cisplatin as a radio-sensitizer (6) (7) (8) (9) , other studies have reported lack of radiosensitization activity (10, 11) , or increased patient survival with high toxicity (8) .
Molecular mechanisms of radio-sensitization by cisplatin are not completely understood. However, inhibition of repair of radiation-induced DNA damage by cisplatin is thought to be the underlying mechanism (12, 13) . Cisplatin has been shown to prevent the translocation of Ku protein along DNA which affects non-homologous end joining pathway thus contributing to cell death (14) . There are reports demonstrating that cisplatin treatment can increase DNA repair and enhance survival of cells after radiation exposure (15, 16) .
The dual clinical objectives of the combined modality treatment, improved local control and prevention of distant micrometastases are constrained by the intrinsic radiation-and chemo-resistance of solid cancers causing profound patient morbidity. 4 sensitivity (HRS) at doses of < 0.5Gy and induced radiation resistance (IRR) at doses of >1Gy are well documented (15, 21) . HRS does not induce cellular repair mechanisms often observed at clinically relevant or higher radiation doses and thus provides a plausible explanation as to why there is no induction of radiation resistance with HRS as measured in vitro (21) . Further, HRS inducing low dose failed to induce pro-survival transcription factors such as NFκB and NF-Y that is necessary for increasing the levels of MDR-1 gene (22) . Hence, low or no MDR-1 induction in response to LDFRT will help to enhance the effects of chemotherapy that is often mitigated by MDR-1. Critically, to take advantage of the benefits of HRS in the clinical setting, radiotherapy would have to be extended over 7-12 weeks (ultrafractionation) to reach a total dose equivalent to that of standard radiation therapy approaches. Realistically, prolongation of radiation therapy using LDFRT in clinical settings is not possible due to the cost factor as well as biologically there is no clear evidence whether such HRS phenomenon exists in vivo. In order to avoid such issues, the enhanced cell killing effects of low dose fractionated radiation therapy (LDFRT) in the form of HRS can be exploited by combining it with chemotherapy. The present study investigates the effects of cisplatin in NSCLC cell lines, H-157, H460, A549 and UKY-29, in combination with LDFRT as well as conventional dose of radiation. Studies were designed to understand the mechanisms underlying cisplatin-potentiation effects by LDFRT as well as the role of HRS in determining the cellular response and mode of cell killing. The findings indicate that chemo-potentiation by LDFRT is correlated more with the intrinsic radiation sensitivity of the cells than the HRS phenomenon while the cell killing is rendered either by apoptosis or clonogenic inhibition. Table 1 ). All cell lines were cultured at 37 o C and 5% CO 2 in RPMI supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
MATERIAL AND METHODS

Cell
Cell Treatments
Cells were treated with cisplatin (Bedford Laboratories, Bedford, OH) formulated in 0.9% sodium chloride at a stock concentration of 1mg/ml. A 100kV industrial X-ray machine (Phillips, Hamburg, Germany) was used to irradiate the cells at room temperature. The dose rate with a 2mm Al plus 1mm Be filter was ~2.64Gy/min at a focus surface distance of 10.5cm.
Treatments were performed in the following manner; (1) left untreated (UT); (2) 0.1Gy to 6Gy dose of radiation; (3) cisplatin (for H-157, 0.025μg/ml to 0.5μg/ml; for UKY-29, 0.01μg/ml to 0.5μg/ml; for both H460 and A549, 0.01μg/ml to 0.5μg/ml). 6 combined treatments (cisplatin plus radiation), the cells were treated with cisplatin (H-157, 0.04μg/ml; H460 and UKY-29, 0.25μg/ml; A549, 0.3μg/ml) and immediately exposed to radiation unless specified otherwise without changing the medium. For multifractionated experiments, cells were exposed to radiation without changing the medium at 0.5Gy in four fractions, with 8h time intervals between each fraction. In a separate set of experiments, cells were exposed to a total dose of 6Gy (2Gy, 1Gy and 0.5Gy fractions) using an 8h time interval between each fraction.
Colony forming assay
Clonogenic survival assays were performed for each treatment group as described previously (17, 18, 24) . Briefly, for each treatment, cells were plated in two different cell 
Quantification of apoptosis
Flow-cytometric analysis:
Untreated (UT) or treated cells as described above were incubated in growth media for specific periods of time (from 0 to 48h). Adherent and floating cells were harvested by trypsinization. Flow-cytometric measurements of cellular DNA content were performed in ethanol-fixed cells using propidium iodide (PI) as described earlier (25) . PI stained cellular DNA was excited at 488nm using flow-cytometer (FACS Calibur; Beckton and Dickenson, USA) and the data was acquired using the Cell Quest software (Beckton and Dickenson, USA). Apoptotic cells were quantified gating sub G 0 /G 1 population.
TUNEL assay:
The in situ apoptosis detection kit (Roche Diagnostics Corporation, Indianapolis, IN) which detects the DNA strand breaks in single cells by terminal transferase mediated fluorescein-dUTP end labeling (TUNEL) was used as per the instructions provided by the manufacturer. Cells were seeded in chamber slides and exposed to cisplatin alone (IC 50 concentrations); 2Gy, single fraction (2Gy); combination of cisplatin and 2Gy, single dose (cisplatin+2Gy); and cisplatin plus four fractions of 0.5Gy (cisplatin+LDFRT).
After 24h and 48h of treatment, cells were stained using TUNEL kit. The stained slides were observed in triple band-pass filter using Nikon-microphoto epifluorescence Table 2 ) involved in apoptosis using Applied Biosystems 7300 instrument.
Western blot analysis
Total protein extracts obtained at 6h after treatment of A549 cells were subjected to Western blot analysis as previously described (26) . Briefly membranes were incubated overnight at 4 0 C with primary antibodies against XIAP (BD Bioscience). The same membrane was stripped and reprobed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling) as previously described (27) . Densitometric analysis was done using the NIH ImageJ software (http://rsb.info.nih.gov/ij/). Inc., Cary, NC). Type-I error rate was set to 5% if not stated otherwise due to multiple testing.
RESULTS
HRS phenomenon was present in H-157, UKY-29 and A549 cells but not in H460 cells
To investigate the presence of HRS and radiation sensitivity in these cell lines, Figure 1D ). These results were confirmed by statistical analysis as explained in the methods section with a hypothesis that there is no difference in slope of SF of cells between "high" and "low" doses. Overall, there were statistically significant differences in slope of SF between "high" and "low" doses for cell lines H-157, UKY-29, A459 but not for cell line H460 (Supplementary table 3 The IC 50 concentrations were 0.04μg/ml for H-157, 0.25μg/ml for both UKY-29 and H460, and 0.3μg/ml for A549 cells suggesting that H-157 cells were most sensitive to cisplatin treatment and A549 were most resistant. This is similar to the data that was Table 1 ).
Interestingly, chemo-potentiating effects of LDFRT were found to be dependent on the intrinsic radiation sensitivity of the cells ( Figure 3C ). Except H-157 that was the most radio-sensitive cell line with proficient HRS, CER was inversely proportional to radio-resistance both when determined by clonogenic inhibition or apoptosis. Figure 4C ). In both cell lines, however, hypodiploid peak indicating apoptosis was not observed.
Enhanced expression of pro-apoptotic genes was observed in cells demonstrating HRS following LDFRT or combination treatments
We and others have shown earlier that a significant amount of apoptosis is induced by LDFRT (17, 18, 29) . To understand the mechanisms underlying chemo- Figure 5D ). These results suggest that for certain cells that are radio-resistant, use of specific inhibitors of XIAP may be vital for enhancing cell killing with either LDFRT or 2Gy.
DISCUSSION
Our previous in vitro, in vivo and clinical studies have demonstrated that LDFRT
can be used as a chemo-potentiator of paclitaxel, carboplatin and gemcitabine (18) (19) (20) 30) . However, the question that still remains unanswered is whether presence of HRS is essential to potentiate the effects of chemotherapeutic drugs by LDFRT. Since, there are currently no isogenic in vitro HRS models available that can be utilized to delineate the mechanisms of chemopotentiation by LDFRT, in the present study four lung cancer cell lines were used that had different degree of HRS to answer this question. It was observed that H-157, UKY-29 and A549 demonstrated HRS while H460 cells did not (Figure 1) . Although, the reasons for the absence of HRS in some cells are not well understood, it has been suggested that HRS-negative cell lines have a dissociation between ATM activity and early G 2 -phase checkpoint function, producing an aberrant early G 2 checkpoint response that evades dose-dependent ATM regulatory control (31) . However, H460 cells did not show any G 2 -phase arrest after LDFRT ( Figure 4D ). Therefore, some other mechanisms may be responsible in these cells for failure of exhibiting HRS. 
In this study, both radio-resistant cells such as UKY-29 and A549 as well as radio-sensitive cells such as H-157 did demonstrate the presence of HRS. These observations are contrary to the reports that radio-resistant cells express increased HRS/IRR (32) . In fact, the most pronounced HRS was demonstrated in the most radiosensitive H-157 cells suggesting that HRS is not an exclusive phenomenon for radio-resistant tumor cells.
The present study findings strongly suggest that LDFRT can chemo-potentiate the effects of cisplatin in H460 cells that lack HRS phenomenon as well as in H-157, UKY-29 and A549 cells harboring varying degree of HRS. Further, a higher CER was observed with LDFRT compared to single fraction of 2Gy in all the human lung cancer cell lines studied except A549 (Table 1) . More importantly, LDFRT potentiated the effects of cisplatin maximally in H460 cells although they were HRS-negative. In addition, a linear relationship was observed between CER and intrinsic radio-sensitivity of these cell lines ( Figure 3C ). Thus, together these observations demonstrate that chemo-potentiation of cisplatin by LDFRT may be independent of HRS but depend more on intrinsic radiosensitivity of the cells.
A differential response to different types of fractionated radiation exposures was observed in H-157 and H460 cells. HRS-positive H-157 cells were more sensitive to fractions of 0.5Gy (a total dose of 6Gy) than fractions of 1Gy or 2Gy while HRSnegative H460 cells showed no differential effect with either of these fractions ( Figure   2A ). These findings potentially suggest that low-dose fractionated scheme settings may be advantageous in cells that harbor HRS phenomenon. eliminates the sensitive subpopulation so that the remaining cell population are more resistant to subsequent treatments (36) .
Our previous studies in head and neck tumor cell lines and mice xenografts demonstrated increased apoptosis rather than clonogenic death in LDFRT mediated chemo-potentiation (18, 19) suggesting that preferred mode of killing in chemopotentiation by LDFRT is apoptosis. This is supported by the TUNEL assay results of the present study where it was found that chemo-enhancement ratio was significantly higher for apoptosis than clonogenic inhibition in H-157 cells. A relationship between apoptosis and the prevalence of low dose HRS has been demonstrated previously (29) . Hence, HRS-negative H460 cells showed increased clonogenic inhibition than apoptosis when compared to HRS-positive H-157 cells. However, UKY-29 and A549 cells harboring HRS did not demonstrate significant induction of apoptosis following LDFRT thus supporting the previous observations that apoptosis may be indicative of HRS but is not a prerequisite for HRS (37, 38) . Further, in H460 cells significant differences in expression of genes related to apoptosis were not observed with any of the treatments when compared to the untreated group (Supplementary table 6 
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